title: Studies of the action of ceramide-like substances (D- and L-PDMP) on sphingolipid glycosyltransferases and purified lactosylceramide synthase.
abstract: We have studied the effects of D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP) and its L-enantiomer on glycosphingolipids in cultured normal human kidney proximal tubular cells. We found that D-PDMP exerted a concentration-dependent reduction in the metabolic labelling and cellular levels of glucosylceramide (GlcCer), lactosylceramide (LacCer), and the globo-series glycosphingolipids, GbOSe3Cer and GbOse4Cer. It also directly inhibited the activity of UDP-glucose:ceramide beta 1--> 4-glucosyltransferase (GlcT-1) and UDP-galactose: GlcCer beta 1-->4 galactosyltransferase (GalT-2). In contrast, L-PDMP had opposite effects on the metabolic labelling of GlcCer, LacCer, and GbOse3Cer. The levels of GlcCer and LacCer were increased, while the labelling and level of GbOse4Cer were strongly reduced. Purified GalT-2 from human kidney was inhibited by D-PDMP and stimulated by L-PDMP. It appears likely that the different glycosphingolipid glycosyltransferases possess similar binding sites for the ceramide moiety, which are blocked by binding to D-PDMP and, in the case of GbOse4Cer synthase, by L-PDMP as well. The stimulatory effects of L-PDMP on GlcCer and LacCer synthases may be the result of binding to a modulatory site on the glycosyltransferases; in intact cells, the enzyme-analog complex may afford protection against the normal catabolic inactivation of the enzymes.
authors.affiliation: Johns Hopkins University, School of Medicine, Baltimore, MD 21287-3654, USA.
authors.forename: S
authors.initials: S
authors.lastname: Chatterjee
authors.forename: T
authors.initials: T
authors.lastname: Cleveland
authors.forename: W Y
authors.initials: WY
authors.lastname: Shi
authors.forename: J
authors.initials: J
authors.lastname: Inokuchi
authors.forename: N S
authors.initials: NS
authors.lastname: Radin
mesh_terms: D002236:Carbohydrate Conformation; D002240:Carbohydrate Sequence; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005690:Galactose / Q000378:metabolism; D005700:Galactosyltransferases / Q000302:isolation & purification / Q000378:metabolism*; D005964:Glucosyltransferases / Q000378:metabolism*; D006028:Glycosphingolipids / Q000096:biosynthesis*; D006602:Hexosyltransferases / Q000378:metabolism*; D006801:Humans; D007687:Kidney Tubules, Proximal / Q000201:enzymology*; D007700:Kinetics; D008969:Molecular Sequence Data; D009025:Morpholines / Q000494:pharmacology*; D013237:Stereoisomerism
chemical_list: D004791:Enzyme Inhibitors; D006028:Glycosphingolipids; D009025:Morpholines; C033110:RV 538; D005700:Galactosyltransferases; D005964:Glucosyltransferases; D006602:Hexosyltransferases; C039090:UDPgalactose-glucosylceramide galactosyltransferase; C023235:glucosylceramide beta-1-4-galactosyltransferase; C023246:ceramide glucosyltransferase; D005690:Galactose